ClinicalTrials.gg
DrugBiological

Digoxin antibodies Fab fragments clinical trials

studies test it
4
open now
0
in phase 3
1
first study started
2007

How each study uses digoxin antibodies Fab fragments is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
22 Apr 1986 · Digibind · BLA 103141 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Digoxin Antibodies Fab Fragments
1

Brand

DigiFab
1
Digibind
1

Other names

Digoxin immune fab
1

Studies by the year they started

4 studies that test it; most in 2007 (1)

Studies that test digoxin antibodies Fab fragments, by start year
YearStudies
20071
20091
20171
20191

By phase

A phase 1/2 study counts in both.

Phase 2
2
Phase 3
1
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 1 · Other 3

University of Maryland, Baltimore (1) · Rambam Health Care Campus (1) · AMAG Pharmaceuticals, Inc. (1) · National Institute on Aging (NIA) (1)

Studies

Open first, then newest update. How each study uses digoxin antibodies Fab fragments is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Codes

What other systems call digoxin antibodies Fab fragments · ClinicalTrials.gg INT003293

  • MeSH (NLM) C050199digoxin antibodies Fab fragmentsOne source ClinicalTrials.gov
  • RxNorm 1745257One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.